Clinical Trial Update: Study to Evaluate Safety and Efficacy of CCX 354-C in Subjects With Rheumatoid Arthritis [Phase 1, Phase 2]

View source ↗

Summary

Amgen completed a combined Phase 1/2 trial to evaluate the safety and efficacy of CCX-354-C in rheumatoid arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• CCX-354-C (CCX-354-C)

Snippet

Sponsor: Amgen | Conditions: Rheumatoid Arthritis | Phase 1, Phase 2 | Status: COMPLETED